What is claimed is:

1. A compound having the structure:



wherein

R_1 is present or absent, and when present is H, C_1-C_6 alkyl, C_1-C_6 alkynyl, $-(CH_2)_yS(CH_2)_xCH_3$, C_1-C_6 aminoalkyl, C_1-C_6 hydroxyalkyl or $-(CH_2)_nC(=O)(C_6H_4)(CH_2)R_2$;

R_2 is H or C_1-C_4 alkyl;

R_3 is H or C_1-C_4 alkyl;

R_4 is present or absent, and when present is H, C_1-C_6 alkyl, C_1-C_6 alkynyl, $-(CH_2)_yS(CH_2)_xCH_3$, C_1-C_6 aminoalkyl, C_1-C_6 hydroxyalkyl or $-(CH_2)_nC(=O)(C_6H_4)(CH_2)R_2$;

wherein n is an integer from 1-6;

wherein x is 0 or an integer from 1-5 and y is an integer from 1-5, such that $x+y<6$;

at least one of R_1 or R_4 is present;

the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and

the compound is charged when both R_1 and R_4 are present,

or a specific enantiomer thereof or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein at least one of R_1 or R_4 is $-(CH_2)_nC(=O)(C_6H_4)(CH_2)R_2$.

3. The compound of claim 1, wherein at least one of R_1 and R_4 is $-(CH_2)_yS(CH_2)_xCH_3$.

4. The compound of claim 1, having the structure:



wherein

R_1 is present or absent, and when present is H or C_1-C_4 alkyl;

R_2 is H or C_1-C_4 alkyl;

R_3 is H or C_1-C_4 alkyl;

R_4 is present or absent, and when present is H or C_1-C_4 alkyl;

at least one of R_1 or R_4 is present;

the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and

the compound is charged when both R_1 and R_4 are present,

or a specific enantiomer thereof or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4, having the structure:



6. The compound of claim 4, having the structure:



7. The compound of claim 4, having the structure:



8. The compound of claim 4, 5, 6 or 7 wherein at least one of R_1, R_2 and R_3 is C_1-C_4 alkyl.

9. The compound of claim 4 or 6, wherein R_1 is absent and R_4 is present.

10. The compound of claim 4, 5, 6 or 7 wherein the chiral carbon is in the R configuration.

11. The compound of claim 4, 5, 6 or 7 wherein the chiral carbon is in the S configuration.

12. The compound of claim 9, wherein R_1 is absent and R_4 is methyl.

13. The compound of claim 7, wherein

R_1 is H or methyl;

R_2 is H or methyl;

R_3 is H or methyl,

or a pharmaceutically acceptable salt thereof.

14. The pharmaceutically acceptable salt of the compound of any one of claims 1-13, wherein the salt is the chloride, mesylate, maleate, fumarate, tartarate, hydrochloride, hydrobromide, esylate, p-toluenesulfonate, benzoate, acetate, phosphate or sulfate salt.

15. The compound of claim 2 having the structure:



16. The compound of claim 1 having the structure:



17. The compound of claim 3 having the structure:



18. The compound of claim 3 having the structure:



19. The compound of claim 1 having the structure:



20. The compound of claim 2 having the structure:



21. The compound of claim 7, having the structure:



22. The hydrochloride salt of the compound of claim 21.

23. The compound of claim 7, having the structure:



24. The hydrochloride salt of the compound of claim 23.

25. The compound of claim 7, having the structure:



26. The hydrochloride salt of the compound of claim 25.

27. The compound of claim 7, having the structure:



28. The hydrochloride salt of the compound of claim 27.

29. The compound of claim 5, having the structure:



30. The hydrochloride salt of the compound of claim 29.

31. The compound of claim 6, having the structure:



32. The hydrochloride salt of the compound of claim 31.

33. The compound of claim 4, having the structure:



I⁻

34. The compound of claim 4, having the structure:



35. A method for treating a subject afflicted with a neurologic disorder comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, so as to thereby treat the neurologic disorder in the subject.

36. The method of claim 35, wherein the neurologic disorder is Parkinson's Disease, Alzheimer's Disease, amyotrophic lateral sclerosis, stroke, a neuromuscular disorder, schizophrenia, cerebral infarction, head trauma, glaucoma, facialis or Huntington's Disease.

37. The method of claim 35, wherein the therapeutically effective amount is from about 1 to about 1000 mg/day.

38. A method for treating a subject afflicted with multiple sclerosis comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof so as to thereby treat multiple sclerosis in the subject.

39. The method of claim 38, further comprising administering to the subject a therapeutically effective amount of

levodopa, glatiramer acetate, interferon beta-1b, interferon beta-1a, steroids or Mitoxantrone.

40. The method of claim 38, wherein the therapeutically effective amount is from about 1 to about 1000 mg/day.

41. The method of claim 35 or 38 wherein the therapeutically effective amount of the compound is administered by injection, systemically, orally or nasally.

42. A method for destroying or inhibiting the proliferation of microbes or fungus which comprises contacting the microbes or fungus with a composition comprising the compound of claim 1 and an acceptable carrier.

43. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

44. The pharmaceutical composition of claim 43, further comprising a therapeutically effective amount of levodopa, glatiramer acetate, interferon beta-1b, interferon beta-1a, steroids or Mitoxantrone.

45. The pharmaceutical composition of claim 43, further comprising a therapeutically effective amount of glatiramer acetate.

46. A process for the manufacture of a pharmaceutical composition comprising admixing the compound of claim 1 with a pharmaceutically acceptable carrier.

47. A packaged pharmaceutical composition for treating a neurologic disorder in a subject comprising:

(a) the pharmaceutical composition of claim 43; and

(b) instructions for using the composition for treating the neurologic disorder in the subject.

48. A process of manufacturing the compound of claim 4 comprising the steps of:

(a) reacting



under suitable conditions with an amine exchanging agent in the presence of solvent to provide:



2 ;

(b) treating **2** with a chlorinating agent to provide



3 ;

(c) reacting **3** with



to provide



wherein

R_1 is present or absent, and when present is H or C_1-C_4 alkyl;

R_2 is H or C_1-C_4 alkyl;

R_3 is H or C_1-C_4 alkyl; and

(d) optionally alkylating the product of step (c), wherein R_1 is H, to provide the compound.

49. The process of claim 48, further comprising reacting the product of step (c), wherein R_1, R_2 and R_3 are each H, with 2-bromo-4'-methylacetophenone in a polar solvent in the presence of a base to produce a compound having the structure:



50. The process of claim 49, wherein the polar solvent is acetonitrile and the base is potassium carbonate.

51. The process of claim 48, further comprising reacting the product of step (c), wherein R_1, R_2 and R_3 are each H, with propargyl bromide in a polar solvent in the presence of a base to produce a compound having the structure:



52. The process of claim 51, wherein the polar solvent is acetonitrile and the base is potassium carbonate.

53. The process of claim 48, further comprising reacting the product of step (c), wherein R_1, R_2 and R_3 are each H, with 2-chloroethyl methylsulfide in a polar solvent in the presence of a base, to produce a compound having the structure:



54. The process of claim 53, wherein the polar solvent is acetonitrile and the base is potassium carbonate.

55. The process of claim 48, wherein the amine exchanging agent is a mixture of aqueous NH_2NH_2 and hydrazinium sulfate in ethylene glycol.

56. The process of claim 55, wherein the chlorinating agent is $SOCl_2$.

57. The process of claim 56, wherein R_1 is C_1-C_4 alkyl and R_2 and R_3 are H.

58. The process of claim 48, wherein the alkylating agent in step (d) is methyliodide or dimethyl sulfate.

59. A process of manufacturing a compound having the structure:



wherein

R_1 is C_1-C_4 alkyl;

R_2 is H or C_1-C_4 alkyl; and

R_3 is H or C_1-C_4 alkyl,

comprising reacting a compound having the structure:



with R_1X in a polar solvent in the presence of a base, wherein X is a halogen atom, to produce the compound.

60. The process of claim 59, wherein the polar solvent is acetonitrile and the base is potassium carbonate.

61. A process of manufacturing a compound having the structure:



wherein

R_2 is H or C_1-C_4 alkyl; and

R_3 is H or C_1-C_4 alkyl,

comprising,

a) reacting



under suitable conditions with a methylating agent, in the presence or absence of solvent to provide:



b) reacting the product of step a) with



in the presence of p-toluenesulfonic acid to provide the compound.

62. The process of claim 61, wherein the product of step (b) is further alkylated with an alkylating agent to provide a compound having the structure:



63. The process of claim 61, wherein the methylating agent in step (a) is methyliodide or dimethyl sulfate.

64. The process of claim 62 wherein the methylating agent is methyliodide.

65. A process of manufacturing the compound of claim 19 comprising reacting a compound having the structure:



with propargylamine and p-TsOH in toluene to produce the compound.

66. A process of manufacturing the compound of claim 18 comprising reacting a compound having the structure:



with propargylamine and p-TsOH in toluene to produce the compound.

67. A process of manufacturing the compound of claim 20 comprising reacting a compound having the structure:



with



in a polar solvent to produce the compound.

68. The process of claim 67, wherein the polar solvent is acetonitrile.

69. Use of the compound of any one of claims 1-34 for manufacturing a medicament useful for treating a neurologic disorder in a subject.

70. The use of claim 69, wherein the neurologic disorder is Parkinson's Disease, Alzheimer's Disease, amyotrophic lateral sclerosis, stroke, a neuromuscular disorder, schizophrenia, cerebral infarction, head trauma, glaucoma, facialis or Huntington's Disease.

71. Use of the compound of any one of claims 1-34 for manufacturing a medicament useful for treating multiple sclerosis in a subject.

72. The use of claim 71, wherein the medicament further comprises levodopa, glatiramer acetate, interferon beta-1b, interferon beta-1a, steroids or Mitoxantrone.

73. Use of the compound of any one of claims 1-34 for manufacturing a medicament in a package having instructions for administration of the medicament to treat a neurologic disorder in a subject.